{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:52:43Z","timestamp":1782129163965,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Programa Internacional de Coooperaci\u00f3n","award":["PF-VIGIS-2012-IMSS"],"award-info":[{"award-number":["PF-VIGIS-2012-IMSS"]}]},{"name":"Comisi\u00f3n Sectorial de Investigaci\u00f3n Cient\u00edfica de la Universidad de la Rep\u00fablica"},{"DOI":"10.13039\/501100008441","name":"Programa Iberoamericano de Ciencia y Tecnolog\u00eda para el Desarrollo (CYTED)","doi-asserted-by":"crossref","award":["ME-PA03-SV-027"],"award-info":[{"award-number":["ME-PA03-SV-027"]}],"id":[{"id":"10.13039\/501100008441","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.pharep.2014.06.007","type":"journal-article","created":{"date-parts":[[2014,6,23]],"date-time":"2014-06-23T10:00:18Z","timestamp":1403517618000},"page":"946-951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Chronic administration of phenytoin induces efflux transporter overexpression in rats"],"prefix":"10.1007","volume":"66","author":[{"given":"Silvana","family":"Alvariza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Fagiolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8073-2417","authenticated-orcid":false,"given":"Iris","family":"Feria-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Orozco-Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2014.06.007_bib0005","series-title":"Genetic of epilepsy and refractory epilepsy","year":"2013"},{"key":"10.1016\/j.pharep.2014.06.007_bib0010","series-title":"Pharmacoresistence in epilepsy: from genes and molecules to promising therapies","author":"Fagiolino","year":"2013"},{"key":"10.1016\/j.pharep.2014.06.007_bib0015","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/jpet.103.049858","article-title":"Multidrug resistance protein MRP2 contributes to blood\u2013brain barrier function and restricts antiepileptic drug activity","volume":"306","author":"Potschka","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2014.06.007_bib0020","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1517\/17425251003610640","article-title":"P-glycoprotein related drug interactions: clinical importance and a consideration of disease states","volume":"6","author":"Lee","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.pharep.2014.06.007_bib0025","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/157488506778194910","article-title":"Multidrug-resistance (MDR) protein develops refractory epilepsy phenotype: clinical and experimental evidences","volume":"1","author":"Lazarowski","year":"2006","journal-title":"Curr Drug Ther"},{"key":"10.1016\/j.pharep.2014.06.007_bib0030","series-title":"Pharmacoresistence in epilepsy: from genes and molecules to promising therapies","author":"Lazarowski","year":"2013"},{"key":"10.1016\/j.pharep.2014.06.007_bib0035","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clpt.2004.04.011","article-title":"Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans","volume":"76","author":"Giessmann","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharep.2014.06.007_bib0040","first-page":"908","article-title":"Time-dependent and concentration-dependent upregulation of carbamazepine efflux transporter. A preliminary assessment from salivary drug monitoring","volume":"30","author":"Maldonado","year":"2011","journal-title":"Lat Am J Pharm"},{"key":"10.1016\/j.pharep.2014.06.007_bib0045","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1124\/jpet.107.121178","article-title":"Region-specific overexpression of P-glycoprotein at the blood\u2013brain barrier affects brain uptake of phenytoin in epileptic rats","volume":"322","author":"Van Vliet","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2014.06.007_bib0050","first-page":"379","article-title":"Development of water\/oil emulsion. Bioavailability in rats","volume":"1","author":"Savio","year":"1991","journal-title":"STP Pharm Sci"},{"key":"10.1016\/j.pharep.2014.06.007_bib0055","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0920-1211(94)90020-5","article-title":"Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: phenytoin","volume":"19","author":"Lolin","year":"1994","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.pharep.2014.06.007_bib0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF03190865","article-title":"Expression of genes encoding for drug metabolizing cytochrome P450 enzymes and P-glycoprotein in the rat small intestine; comparison to the liver","volume":"28","author":"Lindell","year":"2003","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.pharep.2014.06.007_bib0065","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1365-2125.1992.tb04089.x","article-title":"Autoinduction and steady state pharmacokinetics of carbamazepine and its major metabolites","volume":"33","author":"Kudriakova","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharep.2014.06.007_bib0070","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1124\/jpet.109.161026","article-title":"CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose","volume":"332","author":"Chaudhry","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2014.06.007_bib0075","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00008571-200309000-00005","article-title":"Differential expression and function of CYP2C isoforms in human intestine and liver","volume":"13","author":"L\u00e4pple","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.pharep.2014.06.007_bib0080","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pharmthera.2005.06.005","article-title":"Expression and function of efflux drug transporters in the intestine","volume":"109","author":"Takano","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharep.2014.06.007_bib0085","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0168-3659(99)00034-6","article-title":"Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery","volume":"62","author":"Benet","year":"1996","journal-title":"J Control Release"},{"key":"10.1016\/j.pharep.2014.06.007_bib0090","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s11095-009-9924-0","article-title":"The role of transporters in the pharmacokinetics of orally administered drugs","volume":"26","author":"Shugarts","year":"2009","journal-title":"Pharm Res"},{"key":"10.1016\/j.pharep.2014.06.007_bib0095","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.tips.2004.06.002","article-title":"Importance of P-glycoprotein at blood\u2013tissue barriers","volume":"25","author":"Fromm","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharep.2014.06.007_bib0100","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jns.2008.02.016","article-title":"Effect of 21-day exposure of phenobarbital, carbamazepine and phenytoin on P-glycoprotein expression and activity in the rat brain","volume":"270","author":"Wen","year":"2008","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.pharep.2014.06.007_bib0105","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0014-2999(02)02235-5","article-title":"Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions 2002","volume":"451","author":"Seegers","year":"2002","journal-title":"Eur J Pharmacol"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114014002187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114014002187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:35:34Z","timestamp":1752611734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2014.06.007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S1734114014002187"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2014.06.007","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic administration of phenytoin induces efflux transporter overexpression in rats","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2014.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}